After yesterday’s look at a biotech company (F-star) who are focused on adaptive approaches with bispecific antibodies using checkpoint and immune agonist targets, we now shift direction within Europe to a completely different concept, although both are tetramer-based.
Oncology R&D can be a stop-start journey that is highly unpredictable and uncertain!
In the third part of our latest mini-series on bispecific antibodies, we now take a look a company who are evaluating this modality as a way to activate NK cells and stimulate the innate immune system. With all the fuss and attention on the adaptive immune system and checkpoint blockade, is there a role for innate immunotherapies?
Rather than look at this aspect as competitive, smart companies are seeking ways to complement existing backbones to determine if the outcomes can be boosted by targeting both innate and adaptive systems in a more coordinated manner.
To find out more about these developments, we talked to Dr Adi Hoess, CEO of Affimed, a German biotech company who are developing innate immunotherapies.
They have certainly been on a roller coaster ride of late, with clinical hold and abandonment of a leading program balanced by encouraging initial data with other projects, so what gives?
To learn more and get a heads up on our latest oncology insights and thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.
Bispecifics in the garden? Who knows!
We’re continuing our preview of the ASCO 2019 annual meeting (Twitter #ASCO19) with a look at a fast-paced area of drug development that is attracting a lot of interest, namely the potential of bispecifics as novel cancer treatments.
On BSB we’ve been following this emerging field for the past five years or so, but at this year’s ASCO we expect to hear clinical data that may offer new insights.
If you’ve been in London this past week, then you may have been at the annual Royal Horticultural Society (RHS) Chelsea Flower Show, which features impressively designed show gardens built around a theme or location. They’re built with great attention to detail just for Chelsea, then at a few days they’re dismantled.
Large cancer meetings like ASCO19 are a bit like that too. We all come together for a few days to mix and mingle then go our separate ways again.
In the spirt of Chelsea, in this post we’re taking a look at what to watch for in the “ASCO19 bispecific garden,” if one were to be made. There’s certainly a surfeit of choice to consider and like flowers, some may flourish under certain conditions, but not others.
To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.